serum and cerebrospinal fluid levels of transthyretin in lewy body disorders with and without dementia血清和脑脊液的转体基因水平路易身体障碍和无痴呆.pdfVIP

Serum and Cerebrospinal Fluid Levels of Transthyretin in Lewy Body Disorders with and without Dementia 1,2 . 1,2,4. 1,2. 1,2 Walter Maetzler * , Youyong Tian , Stephanie Maria Baur , Tina Gauger , ¨ 1,2, Benjamin Schmid1,2, Claudia Schulte1,2, Christian Deuschle1,2, Susanna Heck1,2, Bartholomaus Odoj 1,2 3 1,2 1,2 Anja Apel , Arthur Melms , Thomas Gasser , Daniela Berg 1 Center of Neurology, Department of Neurodegeneration and Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany, 2 DZNE, German Center for Neurodegenerative Diseases, Tuebingen, Germany, 3 Center of Neurology, General Neurology Department, University of Tuebingen, Tuebingen, Germany, 4 Department of Neurology, Nanjing First Hospital of Nanjing Medical University, Nanjing, China Abstract Parkinson’s disease (PD) without (non-demented, PDND) and with dementia (PDD), and dementia with Lewy bodies (DLB) are subsumed under the umbrella term Lewy body disorders (LBD). The main component of the underlying pathologic substrate, i.e. Lewy bodies and Lewy neurites, is misfolded alpha-synuclein (Asyn), and - in particular in demented LBD patients - co-occurring misfolded amyloid-beta (Abeta). Lowered blood and cerebrospinal fluid (CSF) levels of transthyretin (TTR) - a clearance protein mainly produced in the liver and, autonomously, in the choroid plexus - are associated with Abeta accumulation in Alzheimer’s disease. In addition, a recent study suggests that TTR is involved in Asyn clearance. We measured TTR protein levels in serum and cereb